Germany awards €750m to BioNTech and CureVac for Covid-19 vaccines
The German Government has granted a total of up to €750m in funding to domestic firms BioNTech and CureVac to support the work on their respective Covid-19 vaccine candidates.
Secure the cell therapy supply chain from bench to bedside
The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.
BioNTech, which partnered with Pfizer and Fosun Pharma on the BNT162 Covid-19 vaccine programme, will receive €375m from the German Federal Ministry of Education and Research (BMBF).
The funding will go towards boosting vaccine development and manufacturing capabilities in Germany while expanding the number of volunteers in late-stage clinical trials.
BioNTech CEO and co-founder Ugur Sahin said: “We are grateful for the significant support from the BMBF, which is helping us to provide a safe and effective vaccine as soon as possible following regulatory approval.
COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence. GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into:
COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments